Expert Outlook: ResMed Through The Eyes Of 9 Analysts
Portfolio Pulse from Benzinga Insights
Recent analysis of ResMed (NYSE:RMD) by 9 analysts shows a mix of bullish to bearish sentiments, with an updated average 12-month price target of $203.22, indicating a 10.52% increase from the previous target. Analyst actions include maintaining, raising, and announcing ratings with price targets ranging from $180.00 to $227.00. ResMed, a leading respiratory care device company, has shown a positive revenue trend with a 12.48% growth rate as of December 31, 2023, but lags behind industry peers. The company also boasts a high net margin of 17.96% and strong financial health indicators such as ROE and ROA above industry averages.
March 27, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ResMed has received mixed analyst ratings but an overall positive outlook with an increased average price target of $203.22, reflecting a potential upside. The company's strong financial performance and positive revenue trend support this optimistic view.
The increase in the average price target to $203.22, based on recent analyst ratings, suggests a bullish outlook for ResMed. This is supported by the company's strong financial indicators such as a high net margin and positive revenue growth, despite being below industry peers. The mix of bullish to bearish sentiments among analysts indicates a varied perspective on the company's future performance, but the overall positive adjustment in price targets and strong financial health suggest a potential upside for the stock in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100